PROGNOSTIC IMPLICATIONS OF P53 OVEREXPRESSION IN SUPRATENTORIAL ASTROCYTIC TUMORS

被引:74
作者
CHOZICK, BS
PEZZULLO, JC
EPSTEIN, MH
FINCH, PW
机构
[1] BROWN UNIV,DEPT CLIN NEUROSCI,PROVIDENCE,RI
[2] BROWN UNIV,CTR INFORMAT TECHNOL,PROVIDENCE,RI
[3] RHODE ISL HOSP,PROVIDENCE,RI 02902
关键词
ASTROCYTOMA; MULTIVARIATE ANALYSIS; P53; GENE; PROGNOSTIC FACTOR;
D O I
10.1227/00006123-199411000-00005
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
THE WILD-TYPE p53 gene is thought to play a critical role in tumor suppression and has been shown to reverse the transformed phenotype of tumor cells in vitro. Mutational inactivation of this aspect of p53 activity occurs frequently in many human neoplasms, including astrocytomas, and is thought to represent a critical step in tumor progression. We have found previously that the presence of p53 immunoreactivity was significantly associated with malignant astrocytomas arising in younger patients, although occurring infrequently in tumors in older patients. Given that young age is the most consistent clinical factor predictive of longer survival in patients with astrocytomas, this suggested that p53 protein accumulation might be a molecular predictor of enhanced survival. To test this hypothesis, we retrospectively studied the association of p53 overexpression with survival in 149 patients with astrocytomas, using univariate and multivariate analysis to determine its value in predicting survival. Although our analysis reaffirmed the strong association between young age and increased survival, we were unable to demonstrate any difference in survival between patients with Grade III and IV tumors with p53 immunoreactivity compared with those without. Presumably, once a tumor has progressed to high grade, the relative importance of p53 status as a predictor of survival is low, probably because of the large number of accumulated genetic alterations associated with malignant tumors. In contrast, the presence of p53 overexpression in Grade II astrocytomas seemed from survival curves to indicate shorter survival compared with patients who had no p53 immunoreactivity. However, this variable did not quite reach statistical significance (P = 0.08) as an independent predictive variable in multivariate analysis. This may be because of the relatively small population of patients with Grade II tumors that were studied (n = 24). However, patients with histological evidence of malignant degeneration had significantly higher levels of p53 staining than those with no evidence of progression. These data are consistent with the likely role of p53 in driving the clonal expansion of a dominant cell type during malignant progression and suggest that p53 overexpression may prove to be a molecular marker for prognosis in patients with Grade II astrocytomas.
引用
收藏
页码:831 / 837
页数:7
相关论文
共 59 条
[1]   PROGNOSTIC-SIGNIFICANCE OF TP53 ALTERATIONS IN BREAST-CARCINOMA [J].
ANDERSEN, TI ;
HOLM, R ;
NESLAND, JM ;
HEIMDAL, KR ;
OTTESTAD, L ;
BORRESEN, AL .
BRITISH JOURNAL OF CANCER, 1993, 68 (03) :540-548
[2]   ISOLATION OF HUMAN-P53-SPECIFIC MONOCLONAL-ANTIBODIES AND THEIR USE IN THE STUDIES OF HUMAN P53 EXPRESSION [J].
BANKS, L ;
MATLASHEWSKI, G ;
CRAWFORD, L .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 159 (03) :529-534
[3]   EPIDEMIOLOGY OF PRIMARY TUMORS OF BRAIN AND SPINAL-CORD - REGIONAL SURVEY IN SOUTHERN ENGLAND [J].
BARKER, DJP ;
WELLER, RO ;
GARFIELD, JS .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1976, 39 (03) :290-296
[4]   HUMAN P53 IS PHOSPHORYLATED BY P60-CDC2 AND CYCLIN-B-CDC2 [J].
BISCHOFF, JR ;
FRIEDMAN, PN ;
MARSHAK, DR ;
PRIVES, C ;
BEACH, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (12) :4766-4770
[5]  
BURGER PC, 1989, CANCER-AM CANCER SOC, V63, P2014, DOI 10.1002/1097-0142(19890515)63:10<2014::AID-CNCR2820631025>3.0.CO
[6]  
2-L
[7]  
BYAR DP, 1983, ONCOLOGY NERVOUS SYS, P379
[8]   P53 MUTATIONS, ANOTHER BREAST-CANCER PROGNOSTIC FACTOR [J].
CALLAHAN, R .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (11) :826-827
[9]   LONG-TERM SURVIVAL IN PATIENTS WITH GLIOBLASTOMA-MULTIFORME [J].
CHANDLER, KL ;
PRADOS, MD ;
MALEC, M ;
WILSON, CB ;
SALEMAN, M ;
BLACK, PM .
NEUROSURGERY, 1993, 32 (05) :716-720
[10]  
CHANG CH, 1983, CANCER, V52, P997, DOI 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO